Imiquimod cream efficacy in the treatment of periocular XXXX : a non-randomized trial.

@entity1 @entity1491
BACKGROUND: The recurrence rate of periocular @entity1491 (PNBCC) following treatment with imiquimod (IMQ) has not yet been established. Previous studies did not include histological follow-up. The aim of this analysis was to evaluate the efficacy of topical immunotherapy with 5% IMQ cream for the treatment of PNBCC. METHODS: Study design: A prospective, non-randomized, and uncontrolled longitudinal case series study. No @entity1 were blinded. Punch biopsy confirmed PNBCC @entity1 were included at the Ophthalmology Clinic of S  o Paulo University Medicine School Hospital (from 2008 to 2012). @entity1 were treated with 5% IMQ cream once a day, 5  days per week, for 8-16 weeks. Standard lesion photographic documentation was done during the study. Three months after treatment ended, an image-guided biopsy was performed. @entity1 were followed at 6-month intervals and annually for control biopsies. Main outcome measures were clinical and histological clearance rates. Data were analysed by frequency distribution for qualitative group characteristics and central tendency measures for quantitative data. RESULTS: Twenty-four @entity1 met the inclusion criteria, 19 of whom remained until the end of treatment. The histological clearance rate was 89.5% and 84.2%, respectively, at 3 and 39.5  months. The 3-year histological clearance rate was 81.8% (9/11) for lesions >10  mm, and 100% (8/8) for lesions <10  mm. Three @entity1 did not tolerate the side effects of the medication and left the study. Two @entity1 were excluded for treatment interruption related to comorbidities. CONCLUSIONS: Our results indicated that 5% IMQ cream was a useful alternative treatment for NBBCC, especially for lesions <10  mm. IMQ also showed a significant neoadjuvant effect on lesions >10  mm. TRIAL REGISTRATION: ClinicalTrial.gov Registration Dec 3, 2008: # NCT 00803907 .
